CosmosID
CosmosID is a bioinformatics company specializing in rapid microorganism identification in metagenomic samples using AI-integrated multi-omics technology. Founded in 2007 in Rockville, Maryland, it serves microbiome research customers and is now integrated into parent Cmbio's Digital Biology platform.
- Company typePrivate
- Founded2007
- HeadquartersRockville, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What CosmosID does
CosmosID is a bioinformatics company specializing in the rapid identification of microorganisms in metagenomic samples, founded in 2007 and headquartered in Rockville, Maryland. The company builds technology that integrates multi-omics (genomics, metagenomics, and related layers) with AI and systems biology to support microbiome research, discovery, development, and clinical validation workflows. Its capabilities are described as a core component of Cmbio's Digital Biology platform, which combines multi-omics, AI, and systems biology into a unified model for microbiome innovation spanning discovery through commercialization.
CosmosID has historically operated with a small team (11–50 employees) and has raised approximately $7.2M across two funding rounds (2011 and 2016), the most recent led by Applied Value. Its leadership includes CEO Manoj Dadlani, Founder and Chairman Rita R. Colwell (a recognized figure in microbiome science), and CSO Tom Cebula. The company was profiled among 10 Maryland life science companies pioneering AI innovation, signaling reputational positioning at the intersection of microbiome research and applied AI. The company is now associated with parent Cmbio, a Denmark and US-based microbiome innovation company that has expanded through acquisitions and integrated CosmosID's capabilities into its unified platform model.
Pricing is not publicly disclosed, and no customer logos, revenue figures, or go-to-market segmentation details are available in the source data. The absence of post-2016 disclosed funding activity, combined with the documented integration into Cmbio's platform, suggests CosmosID's standalone commercial identity has been substantially subsumed into a parent-led ecosystem strategy. As a result, the unit economics, pricing model, and customer mix for CosmosID as an independent entity are not separately verifiable from available sources.
CosmosID firmographics
Firmographics- Name
- CosmosID
- Website
- https://cosmosid.com
- Company type
- Private
- Founded year
- 2007
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- CosmosID is a bioinformatics company specializing in rapid microorganism identification in metagenomic samples using AI-integrated multi-omics technology. Founded in 2007 in Rockville, Maryland, it serves microbiome research customers and is now integrated into parent Cmbio's Digital Biology platform.
- Ownership category
- akta.pro rank
CosmosID industry classification
Industry- Product category
- Bioinformatics Software
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Computer Systems Design and Related Services (54151)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Computer Programming, Data Processing, Etc. (7370)
- akta.pro primary industry
- Bioinformatics & Multi-omics Analysis Software (HLAGAJAD)
- akta.pro secondary industries
- Microbiome Analytics, Sequencing & Bioinformatics Platforms (HLAAAFAI), Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI), Microbiome Diagnostics & Biomarker Platforms (gut/skin/oral/vaginal) (HLAAAFAH), Microbiome & Metagenomics Services (HLAGANAH)
Keywords
Where CosmosID is headquartered
LocationHeadquarters
- HQ city
- Rockville
- HQ country
- United States
- HQ region
- North America
Markets served
CosmosID business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
CosmosID product offering
Product offeringCore offering
CosmosID is a bioinformatics company that provides metagenomics and microbiome analysis technology for the rapid identification of microorganisms in metagenomic samples. Its platform combines multi-omics technologies with AI and systems biology to support discovery, development, and clinical validation workflows for microbiome research and related applications.
Product overview
CosmosID is a metagenomics and microbiome analysis technology that has been utilized as a component within Cmbio's integrated Digital Biology platform, which combines multi-omics technologies, AI, and systems biology. CosmosID's technology contributes to microbiome discovery, development, and clinical validation workflows.
Differentiator
Problem solved
Functional benefit
Products and services
- CosmosID
Companies that use CosmosID
Customer profileIdeal customer profiles3 records
CosmosID technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
CosmosID partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- CmbiocoreCosmosID was historically utilized by Cmbio as part of their integrated microbiome research platform called Digital Biology. Cmbio has expanded through acquisitions, integrating various scientific capabilities including CosmosID's multi-omics technologies into a unified model. The relationship indicates CosmosID was part of Cmbio's portfolio of entities supporting microbiome innovation from discovery to commercialization.
Scale indicators1 record
Recent moves4 records
Expansion highlights4 records
CosmosID competitors and assessment
Company assessmentEmerging players
- Ginkgo Bioworks: Synthetic biology platform with significant microbiome engineering and analytics capabilities — adjacent in organism-centric data and AI-driven biology workflows.
- Second Genome: Microbiome-focused drug discovery and biomarker company using multi-omics and computational biology — a peer in applying analytics to microbiome therapeutic pipelines.
- Eagle Genomics: AI-driven multi-omics and microbiome analytics platform for R&D, offering knowledge graphs comparable to CosmosID's AI + systems biology positioning.
Direct peers
- DNAnexus: Cloud-based bioinformatics platform for genomic and multi-omic data analysis, comparable as a data infrastructure and analysis layer for life sciences customers.
- Metabolon: Specialized multi-omics services provider combining metabolomics with microbiome and informatics — comparable on the multi-omics analytics model CosmosID applies.
- Diversigen: Microbiome and metagenomics sequencing services provider offering end-to-end analytical workflows, directly comparable to CosmosID's metagenomic identification capabilities.
- Zymo Research: Provides microbiome collection devices, reagents, and bioinformatics services including metagenomic analysis — overlapping with CosmosID's core offering.
Broad incumbents
- Illumina: Dominant sequencing platform vendor increasingly moving into secondary analysis and bioinformatics for microbial and metagenomic applications — overlaps at the data layer.
- QIAGEN: Major life science tools provider with a bioinformatics portfolio (including via Diversigen) — a broader incumbent competing in microbiome sample-to-insight workflows.
- Bio-Rad Laboratories: Diversified life science tools vendor with digital PCR, sequencing, and bioinformatics offerings touching microbiome research customers.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
CosmosID social profiles
Digital presenceCosmosID financial estimates
Financial estimateRevenue estimate
Valuation estimate
CosmosID leadership team
Management profileNumber of profiles
Profiles3 records
CosmosID funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CosmosID M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CosmosID
What does CosmosID do?
CosmosID is a bioinformatics company that provides metagenomics and microbiome analysis technology for the rapid identification of microorganisms in metagenomic samples. Its platform combines multi-omics technologies with AI and systems biology to support discovery, development, and clinical validation workflows for microbiome research and related applications.
When was CosmosID founded?
CosmosID was founded in 2007. It employs 11 to 50 people.
Where is CosmosID based?
CosmosID is headquartered in Rockville, United States, in the North America region.
Who are CosmosID's main competitors?
Emerging players on record are Ginkgo Bioworks, Second Genome and Eagle Genomics. Direct peers are DNAnexus, Metabolon, Diversigen and Zymo Research. Broad incumbents are Illumina, QIAGEN and Bio-Rad Laboratories.
Does CosmosID have an API?
No public API is recorded for CosmosID.
What industry is CosmosID in?
CosmosID's product category is Bioinformatics Software. Its primary akta.pro industry code is HLAGAJAD, Bioinformatics & Multi-omics Analysis Software, with a secondary code of HLAAAFAI, Microbiome Analytics, Sequencing & Bioinformatics Platforms. Its NAICS code is 541714 and its SIC code is 8731.